Showing results (1-10 of 5,543) with videos related to
Sort By:
Pageof 555
Cell|March 19, 2021
Antivirals with common targets against highly pathogenic virusesLu Lu, Shan Su, Haitao Yang, et al.Molecules (Basel, Switzerland)|November 22, 2017
Adding an Artificial Tail-Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance ProfileShan Su, Zhenxuan Ma, Chen Hua, et al.Trends in Immunology|February 7, 2022
Developing pan-β-coronavirus vaccines against emerging SARS-CoV-2 variants of concernShan Su, Weihua Li, Shibo JiangNature Reviews. Microbiology|October 17, 2020
Learning from the past: development of safe and effective COVID-19 vaccinesShan Su, Lanying Du, Shibo JiangAdvances in Experimental Medicine and Biology|April 12, 2022
Virus Entry Inhibitors: Past, Present, and FutureShan Su, Wei Xu, Shibo JiangAIDS (London, England)|April 2, 2019
Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41Wei Xu, Jing Pu, Shan Su, et al.AIDS (London, England)|January 26, 2017
A novel HIV-1 gp41 tripartite model for rational design of HIV-1 fusion inhibitors with improved antiviral activityShan Su, Qian Wang, Wei Xu, et al.Molecules (Basel, Switzerland)|March 24, 2019
A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-LifeShan Su, Giselle Rasquinha, Lanying Du, et al.AIDS (London, England)|November 24, 2015
Co-delivery of HIV-1 entry inhibitor and nonnucleoside reverse transcriptase inhibitor shuttled by nanoparticles: cocktail therapeutic strategy for antiviral therapyWen Li, Fei Yu, Qian Wang, et al.Trends in Immunology|February 1, 2024
SARS-CoV-2 evolution from the BA.2.86 to JN.1 variants: unexpected consequencesXinling Wang, Lu Lu, Shibo JiangPageof 555